İstinadlar

Əsas məqalələr

American Diabetes Association. Standards of medical care in diabetes - 2018. Diabetes Care. 2018 Jan; 41(suppl 1): S1-159.Tam mətn external link opens in a new window

Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Sep 12;352(9131):854-65.Abstrakt external link opens in a new window

Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016 Jun 7;164(11):740-51.Abstrakt external link opens in a new window

Cushman WC, Evans GW, Byington RP, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575-85.Abstrakt external link opens in a new window

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015 Mar;58(3):429-42.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 Jan 30;348(5):383-93.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

İstinadlar

1. Meigs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes. 2003 Jun;52(6):1475-84.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

2. American Diabetes Association. Standards of medical care in diabetes - 2018. Diabetes Care. 2018 Jan; 41(suppl 1): S1-159.Tam mətn external link opens in a new window

3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047-53.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

4. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004 Jul;88(4):787-835, ix.Abstrakt external link opens in a new window

5. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014 Apr 17;370(16):1514-23.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

6. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2017.Tam mətn external link opens in a new window

7. Wormser D, Kaptoge S, Di Angelantonio E, et al; Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011 Mar 26;377(9771):1085-95.Abstrakt external link opens in a new window

8. National Diabetes Data Group. Diabetes in America. 2nd edition. NIH Publication No. 95-1468. January 1995 [internet publication].Tam mətn external link opens in a new window

9. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

10. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997 Apr;20(4):537-44.Abstrakt external link opens in a new window

11. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

12. Gerstein HC, Yusuf S, Bosch J, et al; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006 Sep 23;368(9541):1096-105.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

13. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018 Feb 10;391(10120):541-51.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

14. Coustan DR, Carpenter MW, O'Sullivan PS, et al. Gestational diabetes: predictors of subsequent disordered glucose metabolism. Am J Obstet Gynecol. 1993 Apr;168(4):1139-44; discussion 1144-5.Abstrakt external link opens in a new window

15. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes in America. 3rd edition. Bethesda, MD: National Institutes of Health, NIH Pub No. 17-1468; 2017.Tam mətn external link opens in a new window

16. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA. 2015 Sep 8;314(10):1021-9.Abstrakt external link opens in a new window

17. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

18. Balk EM, Earley A, Raman G, et al. Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Ann Intern Med. 2015 Sep 15;163(6):437-51.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

19. Knowler WC, Fowler SE, Hamman RF, et al; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14;374(9702):1677-86.Abstrakt external link opens in a new window

20. Hemmingsen B, Sonne DP, Metzendorf MI, et al. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;(5):CD012204.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

21. Holman RR, Haffner SM, McMurray JJ, et al; NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010 Apr 22;362(16):1463-76.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

22. McMurray JJ, Holman RR, Haffner SM, et al; NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010 Apr 22;362(16):1477-90.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

23. Roberts S, Barry E, Craig D, et al. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open. 2017 Nov 15;7(11):e017184.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

24. Haw JS, Galaviz KI, Straus AN, et al. Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2017 Dec 1;177(12):1808-17.Abstrakt external link opens in a new window

25. Herman WH, Pan Q, Edelstein SL, et al; Diabetes Prevention Program Research Group. Impact of lifestyle and metformin interventions on the risk of progression to diabetes and regression to normal glucose regulation in overweight or obese people with impaired glucose regulation. Diabetes Care. 2017 Dec;40(12):1668-77.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

26. Cohen RM. A1C: does one size fit all? Diabetes Care. 2007 Oct;30(10):2756-8.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

27. Jørgensen ME, Bjerregaard P, Borch-Johnsen K, et al. New diagnostic criteria for diabetes: is the change from glucose to HbA1c possible in all populations? J Clin Endocrinol Metab. 2010 Nov;95(11):E333-6.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

28. Mostafa SA, Khunti K, Webb DR, et al. A comparison of performance from using two HbA1c cut-points (a ‘rule-in, rule-out’ spectrum) and one HbA1c cut-point to detect type 2 diabetes in a multi-ethnic cohort. Diabetologia. 2010;53(suppl 1):S86.Tam mətn external link opens in a new window

29. Dabelea D, Rewers A, Stafford JM, et al; SEARCH for Diabetes in Youth Study Group. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. Pediatrics. 2014 Apr;133(4):e938-45.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

30. Newton CA, Raskin P. Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences. Arch Intern Med. 2004 Sep 27;164(17):1925-31.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

31. Umpierrez GE, Kitabchi AE. Diabetic ketoacidosis: risk factors and management strategies. Treat Endocrinol. 2003;2(2):95-108.Abstrakt external link opens in a new window

32. Sacks DB, Arnold M, Bakris GL, et al; National Academy of Clinical Biochemistry. Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011 Jun;34(6):1419-23.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

33. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013 Jul;30(7):803-17.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

34. Leighton E, Sainsbury CA, Jones GC. A practical review of C-peptide testing in diabetes. Diabetes Ther. 2017 Jun;8(3):475-87.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

35. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005 Sep;28(9):2289-304.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

36. O'Neal KS, Johnson JL, Panak RL. Recognizing and appropriately treating latent autoimmune diabetes in adults. Diabetes Spectr. 2016 Nov;29(4):249-52.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

37. Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab. 2009 Dec;94(12):4635-44.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

38. Pihoker C, Gilliam LK, Ellard S, et al; SEARCH for Diabetes in Youth Study Group. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab. 2013 Oct;98(10):4055-62.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

39. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011 Aug;34(8):1878-84.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

40. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001 Sep 27;345(13):971-80.Abstrakt external link opens in a new window

41. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014 Jan;37(suppl 1):S81-90.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

42. Steenkamp DW, Alexanian SM, Sternthal E. Approach to the patient with atypical diabetes. CMAJ. 2014 Jun 10;186(9):678-84.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

43. Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev. 2008 May;29(3):292-302.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

44. Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006 Mar 7;144(5):350-7.Abstrakt external link opens in a new window

45. US Preventive Services Task Force. Screening for gestational diabetes mellitus. December 2016 [internet publication].Tam mətn external link opens in a new window

46. US Preventive Services Task Force. Abnormal blood glucose and type 2 diabetes mellitus: screening. October 2015 [internet publication].Tam mətn external link opens in a new window

47. Sherifali D, Bai JW, Kenny M, et al. Diabetes self-management programmes in older adults: a systematic review and meta-analysis. Diabet Med. 2015 Nov;32(11):1404-14.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

48. Pillay J, Armstrong MJ, Butalia S, et al. Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis. Ann Intern Med. 2015 Dec 1;163(11):848-60.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

49. Chatterjee S, Davies MJ, Heller S, et al . Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes Endocrinol. 2018 Feb;6(2):130-42.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

50. Fisher L, Hessler D, Glasgow RE, et al. REDEEM: a pragmatic trial to reduce diabetes distress. Diabetes Care. 2013 Sep;36(9):2551-8.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

51. Laiteerapong N, Cooper JM, Skandari MR, et al. Individualized glycemic control for US adults with type 2 diabetes: a cost-effectiveness analysis. Ann Intern Med. 2018 Feb 6;168(3):170-8.Abstrakt external link opens in a new window

52. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Sep 12;352(9131):854-65.Abstrakt external link opens in a new window

53. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

54. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016 Jun 7;164(11):740-51.Abstrakt external link opens in a new window

55. Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013 May;36(5):1304-11.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

56. Gerstein HC, Miller ME, Genuth S, et al; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011 Mar 3;364(9):818-28.Abstrakt external link opens in a new window

57. Patel A, MacMahon S, Chalmers J, et al; The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560-72.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

58. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129-39.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

59. Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

60. Hansen MB, Jensen ML, Carstensen B. Causes of death among diabetic patients in Denmark. Diabetologia. 2012 Feb;55(2):294-302.Abstrakt external link opens in a new window

61. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015 Oct 29;373(18):1720-32.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

62. Desai JR, Vazquez-Benitez G, Xu Z, et al. Who must we target now to minimize future cardiovascular events and total mortality? Lessons from the surveillance, prevention and management of diabetes mellitus (SUPREME-DM) cohort study. Circ Cardiovasc Qual Outcomes. 2015 Sep;8(5):508-16.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

63. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014 May;174(5):773-85.Abstrakt external link opens in a new window

64. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

65. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

66. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892-1903.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

67. Cushman WC, Evans GW, Byington RP, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575-85.Abstrakt external link opens in a new window

68. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf. 2005;28(7):601-31.Abstrakt external link opens in a new window

69. Williams B, MacDonald TM, Morant S, et al; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015 Nov 21;386(10008):2059-68.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

70. Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013 Jul 3;310(1):46-56.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

71. Elam MB, Ginsberg HN, Lovato LC, et al; ACCORDION Study Investigators. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017 Apr 1;2(4):370-80.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

72. Giugliano RP, Cannon CP, Blazing MA, et al; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients With versus without diabetes mellitus: results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 Apr 10;137(15):1571-82.Abstrakt external link opens in a new window

73. Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713-22.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

74. Squizzato A, Suter MB, Nerone M, et al. PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis. Intern Emerg Med. 2017 Oct;12(7):1043-53.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

75. Koegelenberg CF, Noor F, Bateman ED, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA. 2014 Jul;312(2):155-61.Abstrakt external link opens in a new window

76. Bibbins-Domingo K; US Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2016 Jun 21;164(12):836-45.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

77. Cradock KA, ÓLaighin G, Finucane FM, et al. Diet behavior change techniques in type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2017 Dec;40(12):1800-10.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

78. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2960-84.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

79. Bolen S, Tseng E, Hutfless S, et al. Diabetes medications for adults with type 2 diabetes: an update. Comparative Effectiveness Reviews, no. 173. Rockville, MD: Agency for Healthcare Research and Quality (US); 2016.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

80. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015 Mar;58(3):429-42.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

81. US Food and Drug Administration. FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. April 2016 [internet publication].Tam mətn external link opens in a new window

82. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 Aug 17;377(7):644-57.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

83. Cherney DZ, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-21.Abstrakt external link opens in a new window

84. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

85. Mahaffey KW, Neal B, Perkovic V, et al; CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: results From the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018 Jan 23;137(4):323-34.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

86. US Food and Drug Administration (FDA). FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). June 2016 [internet publication].Tam mətn external link opens in a new window

87. US Food and Drug Administration (FDA). FDA drug safety communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). May 2017 [internet publication].Tam mətn external link opens in a new window

88. European Medicines Agency (EMA). SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information. February 2017 [internet publication].Tam mətn external link opens in a new window

89. Medicines and Healthcare products Regulatory Agency. MHRA drug safety update: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes). March 2017 [internet publication].Tam mətn external link opens in a new window

90. Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017 Apr;19(4):524-36.Abstrakt external link opens in a new window

91. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007 Jul 11;298(2):194-206.Abstrakt external link opens in a new window

92. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

93. Gross JL, Kramer CK, Leitão CB, et al; for the Diabetes and Endocrinology Meta-analysis Group (DEMA). Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med. 2011 May 17;154(10):672-9.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

94. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457-71.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

95. European Medicines Agency (EMA). Questions and answers on the suspension of rosiglitazone-containing medicines (Avandia, Avandamet and Avaglim). September 2010 [internet publication].Tam mətn external link opens in a new window

96. Bach RG, Brooks MM, Lombardero M, et al. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2013 Aug 20;128(8):785-94.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

97. US Food and Drug Administration. PFDA Drug Safety Communication: updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer. December 2016 [internet publication].Tam mətn external link opens in a new window

98. Scirica BM, Bhatt DL, Braunwald E, et al; the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 3;369(14):1317-26.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

99. White WB, Cannon CP, Heller SR, et al; the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 3;369(14):1327-35.Abstrakt external link opens in a new window

100. Toh S, Hampp C, Reichman ME, et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med. 2016 Jun 7;164(11):705-14.Abstrakt external link opens in a new window

101. Filion KB, Azoulay L, Platt RW, et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med. 2016 Mar 24;374(12):1145-54.Abstrakt external link opens in a new window

102. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012 Apr 26;366(17):1567-76.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

103. Schauer PR, Bhatt DL, Kirwan JP, et al; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376:641-51.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

104. Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013 Aug;36(8):2175-82.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

105. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013 Jun 5;309(21):2240-9.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

106. Halperin F, Ding SA, Simonson DC, et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg. 2014 Jul;149(7):716-26.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

107. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012 Aug 23;367(8):695-704.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

108. Nielsen GL, Møller M, Sørensen HT. HbA1c in early diabetic pregnancy and pregnancy outcomes: a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes. Diabetes Care. 2006 Dec;29(12):2612-6.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

109. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. August 2015 [internet publication].Tam mətn external link opens in a new window

110. Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013 Apr 25;368(17):1613-24.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

111. Bodenheimer T, Wagner E, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model. JAMA. 2002 Oct 9;288(14):1775-9.Abstrakt external link opens in a new window

112. Shojania KG, Ranji, SR, McDonald KM, et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta regression analysis. JAMA. 2006 Jul 26;296(4):427-40.Abstrakt external link opens in a new window

113. McLean DL, McAlister FA, Johnson JA, et al. A randomized controlled trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists - hypertension (SCRIP-HTN). Arch Intern Med. 2008 Nov 24;168(21):2355-61.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

114. O’Connor PJ, Sperl-Hillen JM, Rush WA, et al. Impact of electronic health record clinical decision support on diabetes care: a randomized trial. Ann Fam Med. 2011 Jan-Feb;9(1):12-21.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

115. Sabatine MS, Giugliano RP, Wiviott SD, et al; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1500-9.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

116. Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT Trial. J Am Coll Cardiol. 2016 Feb 2;67(4):353-61.Abstrakt external link opens in a new window

117. US Food and Drug Administration (FDA). Information for consumers (drugs): use of aspirin for primary prevention of heart attack and stroke. June 2014 [internet publication].Tam mətn external link opens in a new window

118. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan;32(1):193-203.Abstrakt external link opens in a new window

119. US Food and Drug Administration (FDA). FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. December 2015 [internet publication].Tam mətn external link opens in a new window

120. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-44.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

121. Kaul S. Mitigating Cardiovascular Risk in Type 2 Diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials. Diabetes Care. 2017 Jul;40(7):821-31.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

122. Cinti F, Moffa S, Impronta F, et al. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2017 Oct 3;11:2905-19.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

123. Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017 May;19(5):721-8.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

124. Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018 Mar;20(3):530-40.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

125. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010 Aug 11;304(6):649-56.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

126. Centers for Disease Control (CDC). State-specific trends in chronic kidney failure - United States, 1990-2001. MMWR Morb Mortal Wkly Rep. 2004 Oct 8;53(39):918-20.Abstrakt external link opens in a new window

127. Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004 Aug;27(8):1879-84.Abstrakt external link opens in a new window

128. Barrett-Connor EL, Cohn BA, Wingard DL, et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA. 1991 Feb 6;265(5):627-31.Abstrakt external link opens in a new window

129. Simpson TC, Weldon JC, Worthington HV, et al. Treatment of periodontal disease for glycaemic control in people with diabetes mellitus. Cochrane Database Syst Rev. 2015 Nov 6;(11):CD004714.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

130. Bascones-Martinez A, Matesanz-Perez P, Escribano-Bermejo M, et al. Periodontal disease and diabetes: review of the literature. Med Oral Patol Oral Cir Bucal. 2011 Sep 1;16(6):e722-9.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

131. Pathak RD, Schroeder EB, Seaquist ER, et al. Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005-2011. Diabetes Care. 2016 Mar;39(3):363-70.Abstrakt external link opens in a new window

132. Davis SN, Umpierrez GE. Diabetic ketoacidosis in type 2 diabetes mellitus - pathophysiology and clinical presentation. Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):730-1.Abstrakt external link opens in a new window

133. Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009 Jul;32(7):1335-43.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

134. Beaulieu N, Cutler D, Ho K, et al. The business case for diabetes disease management for managed care organizations. Forum Health Econ Policy. 2006;9:Article 1.Tam mətn external link opens in a new window

135. Ang L, Jaiswal M, Martin C, et al. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

136. Rustad JK, Musselman DL, Nemeroff CB. The relationship of depression and diabetes: pathophysiological and treatment implications. Psychoneuroendocrinology. 2011 Oct;36(9):1276-86.Abstrakt external link opens in a new window

137. Pamidi S, Tasali E. Obstructive sleep apnea and type 2 diabetes: is there a link? Front Neurol. 2012 Aug 13;3:126.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

138. Shaw JE, Punjabi NM, Naughton MT, et al. The effect of treatment of obstructive sleep apnea on glycemic control in type 2 diabetes. Am J Respir Crit Care Med. 2016 Aug 15;194(4):486-92.Abstrakt external link opens in a new window

139. Martínez-Cerón E, Barquiel B, Bezos AM, et al. Effect of continuous positive airway pressure on glycemic control in patients with obstructive sleep apnea and type 2 diabetes: a randomized clinical trial. Am J Respir Crit Care Med. 2016 Aug 15;194(4):476-85.Abstrakt external link opens in a new window

140. Norris SL, Nichols PJ, Caspersen CJ, et al. Increasing diabetes self-management education in community settings: a systematic review. Am J Prev Med. 2002 May;22(suppl 4):39-66.Abstrakt external link opens in a new window

141. Powers MA, Bardsley J, Cypress M, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care. 2015 Jul;38(7):1372-82.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

142. Prochaska JO, Velicer WF, Rossi JS, et al. Stages of change and decisional balance for 12 problem behaviors. Health Psychol. 1994 Jan;13(1):39-46.Abstrakt external link opens in a new window

143. Young LA, Buse JB, Weaver MA, et al; Monitor Trial Group. Glucose self-monitoring in non-insulin-treated patients with type 2 diabetes in primary care settings: a randomized trial. JAMA Intern Med. 2017 Jul 1;177(7):920-9.Abstrakt external link opens in a new window

144. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. May 2017 [internet publication].Tam mətn external link opens in a new window

145. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone for myocardial infarction and cardiovascular death. Ann Intern Med. 2007 Oct 16;147(8):578-81.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

146. Malanda UL, Welschen LM, Riphagen II, et al. Self monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev. 2012 Jan 18;(1):CD005060.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

147. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 Jan 30;348(5):383-93.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

148. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004 Jan 21;291(3):335-42.Tam mətn external link opens in a new windowAbstrakt external link opens in a new window

Bu məlumatların istifadəsi açıqlama məlumatları ilə tənzimlənir.